Testogel (testosterone replacement therapy)

Testogel is a widely recognized brand of testosterone replacement therapy (TRT) formulated as a transdermal gel. It was originally developed to treat male hypogonadism and has become a leading prescription brand in Europe and Australasia for patients requiring hormonal stabilization. The product is manufactured across several pharmaceutical hubs in Europe to ensure supply chain consistency for global markets.

The brand was originally established by Besins Healthcare, a company with deep roots in hormone therapy innovation. Over the years, the commercial rights and distribution have been managed through various partnerships, most notably with Bayer in several international markets and AbbVie (formerly part of Abbott Laboratories) in others. Today, the brand's ownership structure remains tied to Besins Healthcare, which operates as a global pharmaceutical entity specializing in gynecological, fertility, and andrological treatments.

As of the mid-2020s, the brand continues to be part of the Besins Healthcare portfolio. The company is headquartered in Monaco and maintains a strong manufacturing and research presence in France and Belgium, positioning Testogel as a key product in the global men's health market.